Application of excimer laser coronary atherectomy in treatment of coro-nary atherosclerotic heart disease by drug-coated balloon dilatation
Aim:To investigate the application of excimer laser coronary atherectomy(ELC A)in the treatment of coro-nary atherosclerotic heart disease(CAD)by drug-coated balloon dilatation(DCB).Methods:A total of 86 patients with CAD diagnosed and treated from May 2020 to May 2022 were selected and allocated into observation group(treated with DCB combined with ELCA)and control group(treated with DCB alone)according to the random number ranking method,with 43 cases in each group.Creatine kinase isoenzyme(CK-MB),cardiac troponin Ⅰ(cTn Ⅰ),brain natriuretic peptide(BNP),N-terminal pro-brain natriuretic peptide(NT-proBNP),small dense low-density lipoprotein(sd-LDL),growth dif-ferentiation factor-15(GDF-15),left ventricular end systolic dimension(LVESD),left ventricular ejection fraction(LVEF),left ventricular end diastolic dimension(LVEDD)and major adverse cardiovascular event(MACE)were recorded.Result:After treatment,the decrease degree of CK-MB,cTn Ⅰ,BNP,NT-proBNP,sd-LDL,GDF-15,LVESD and LVEDD,and the increase degree of LVEF in observation group were larger than those in control group(P＜0.05).The incidence of MACE in observation group was lower than that in control group(P=0.019).Conclusion:ELCA combined with DCB is effective in the treatment of CAD,which is conducive to improving cardiac function,alleviating myocardial injury,and reducing the inci-dence of MACE.
万方数据
维普
